Related Experiment Videos
[Thrombolysis in myocardial infarction. Current status. Prospects]
Insights
Thrombolysis for acute myocardial infarction shows variable success in restoring blood flow. However, its effectiveness in limiting infarct size and preserving heart function remains uncertain due to conflicting research and varied protocols.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Acute myocardial infarction (AMI) involves coronary artery obstruction in ~90% of cases within 4 hours.
- Spontaneous reperfusion occurs in 30% by 12 hours and 50% by 3 weeks.
- Thrombolytic agents like streptokinase and urokinase can restore coronary blood flow.
Purpose:
- To review the controversies and data surrounding thrombolysis in acute myocardial infarction.
- To assess the effectiveness of thrombolysis in limiting infarct size and preserving cardiac function.
Summary:
- Intracoronary streptokinase achieves early renewed flow in 85% of cases.
- Parenteral streptokinase or urokinase yields 55-70% renewed flow.
- Determining the superiority of thrombolytic techniques is hindered by diverse protocols and insufficient randomized studies.
Impact:
- Therapeutic fibrinolysis for AMI is currently considered a research modality.
- Further research is needed to establish the definitive efficacy of thrombolysis in preserving ischemic myocardium.
- Contradictory published results and technical constraints necessitate cautious application.
Abstract:
Numerous data and controversies have arisen from studies concerning thrombolysis in acute myocardial infarction over the past five years. It is known that coronary artery obstruction is present in approximately 90 percent of acute infarctions during the first 4 hours of onset. Spontaneous renewed flow is noted in 30 percent of cases following the 12th hour, and in 50 percent of cases following the 3rd week. It is possible to obtain early renewed flow in 85 percent of cases with the administration of intracoronary streptokinase, and in 55 to 70 percent of cases with parenteral administration of streptokinase or urokinase. Controversy centers around the effectiveness of thrombolysis in limiting the size of the infarction, thus preserving cardiac function. Due to the numerous different protocols used and the insufficient number of cases reported in randomized studies, it is not possible to determine the superiority of one technique over another in preserving ischemic myocardium. After taking into account the technical constraints of the procedure and the contradictory published results, therapeutic fibrinolysis should remain a research modality as long as its effectiveness in preserving ischemic myocardium has not been established.